Read more VitroScan and Radboudumc join forces to advance novel cell therapy for ovarian cancer patients

26 May 2026

We are proud to announce the launch of the EXACCT project, a new collaboration between VitroScan and Radboudumc focused on advancing innovative CAR-NK cell therapies for ovarian cancer patients.

Read more

Read more Meet VitroScan at BIO2026!

11 May 2026

VitroScan will be at BIO2026 in San Diego, June 22–25. We look forward to connecting with partners to discuss how our ex vivo micro-tumor testing platform can help de-risk and accelerate oncology drug development by generating clinically relevant efficacy insights earlier in the process.

Read more

Read more VitroScan presented twice at the AACR2026 annual meeting

22 April 2026

Proud to see our very own Felix Behr, PhD presenting twice at the recent #AACR2026 annual meeting with both an oral and a poster presentation showcasing how our ex vivo micro-tumor platform can help characterize and predict patient-specific responses to ADCs and immunotherapies.

Read more

Read more Info Sheet ADC efficacy assessment

1 December 2025

Download our Info sheet on ADC efficacy assessment in VitroScan's ex vivo micro-tumor platform

Read more

Read more Info Sheet Bispecific antibody testing

1 December 2025

Download our Info sheet on bispecific antibody efficacy assessment in VitroScan's ex vivo micro-tumor platform

Read more

Read more Our latest publication at a glance!

1 October 2025

Download our Info sheet on the latest VitroScan publication highlighting the predictive value of our platform

Read more

Read more AACR 2026

8 April 2026

Download our poster: Ex vivo micro-tumor testing platform to characterize and predict patient-specific immunotherapy responses

Read more

Read more VitroScan at SITC 2025

5 November 2025

Download our poster: Ex vivo micro-tumor testing identifies patient-specific anti-tumor immune responses to T cell engager ubamatamab

Read more

Read more VitroScan at ENA 2025

22 October 2025

Download our poster: Bispecific antibody ubamatamab induces patient-specific anti-tumor immune responses in an ex vivo platform for ovarian cancer

Read more

Read more Koedoot et al., npj Precision Oncology, 2025

30 August 2025

Publication of our study showing that VitroScan's 3D ex vivo micro-tumor testing platform can accurately predict whether an ovarian cancer patient will respond to chemotherapy.

Read more